Disseminate Cutaneous Vasculitis Associated with Durvalumab Treatment—Case Report, Mini-Review on Cutaneous Side Effects of Immune Checkpoint Inhibitor Therapies with Machine Learning Perspectives

Durvalumab is an IgG1 monoclonal antibody that has efficacy in many advanced-stage cancers, especially in small-cell lung cancer. The efficacy of durvalumab can be enhanced by chemotherapy. Cutaneous side effects due to treatment with durvalumab are usually self-limiting and easily manageable. We pr...

Cijeli opis

Bibliografski detalji

Glavni autori:	Gyula Laszlo Fekete, Laszlo Barna Iantovics, Júlia Edit Fekete, Laszlo Fekete
Format:	Artigo
Jezik:	Inglês
Izdano:	MDPI AG 2024-08-01
Serija:	Life
Teme:	small-cell lung cancer cancer immunotherapy durvalumab vasculitis cutaneous side effect
Online pristup:	https://www.mdpi.com/2075-1729/14/9/1062
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!